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Recent developments in vitreoretinal surgery have increased the need for suitable vitreous substitutes. A successful substitute
should maintain all the physical and biochemical properties of the original vitreous, be easy to manipulate, and be long lasting.
Substitutes can be gaseous or liquid, both of which have associated advantages and disadvantages related to their physical
properties and use. Furthermore, new surgical techniques with smaller vitreoretinal instruments have driven the use of more
viscous substitutes. In this review, we analyze and discuss the most frequently used vitreous substitutes and look ahead to future
alternatives. We classify these compounds based on their composition and structure, discuss their clinical use with respect to
their associated advantages and disadvantages, and analyze how new vitreoretinal surgical techniques have modified their use.
1. Introduction
The vitreous body is a clear gel that fills the space between the
lens and the retina. It constitutes approximately 80% of the
volume of the entire eye [1]. In the recent years, the develop-
ment of new surgical techniques and intravitreous-release
drugs has led to a need for improved vitreous substitutes.
The ideal vitreous substitute has all the qualities of the vitre-
ous body (transparency, biocompatibility, volume retention,
elasticity, and durability) and lacks negative characteristics
such as ageing liquefaction and biodegradation. Intensive
research is underway to develop new products that resemble
the vitreous as closely as possible. In this review, we describe
the positive and negative aspects of current and experimental
substitutes and evaluate their use in new surgical techniques
to repair retinal detachment.
2. Method of Literature Search
For this review, a literature search was conducted that utilized
Medline, Premedline, EMBASE, SCOPUS, and Cochrane.
Papers from1950onwardswere includedonvitreous structure
and function while review articles from 2011 onwards were
included on vitreous substitutes. The following search terms
were used: vitreous substitutes, vitreous humour, vitreous
body, ideal vitreous substitutes, tamponade in retinal detach-
ment, gas tamponade in retinal detachment, pneumatic
retinopexy, silicone oil in retinal detachment, heavy silicone
oil in retinal detachment, hydrogel, hydrogel in retinal detach-
ment,microincision vitreoretinal surgery, and vitreous substi-
tutes. References present in relevant articles were used. Only
articles in English were considered.
3. Vitreous
3.1. Anatomy. Each eye contains approximately 4mL of
vitreous, a transparent gel-like structure. The vitreous can
be subdivided into three anatomical regions: the vitreous
core, the vitreous base, and the vitreous cortex. The vitreous
cortex is the part closest to the retina; it exhibits a variable
thickness and a lamellar structure. It contains hyalocytes
and densely packed collagen, similar to the vitreous base
which covers the ora serrata [2]. The vitreoretinal interface
is composed of the internal limiting membrane (ILM), the
innermost part of the retina, and the posterior vitreous. The
ILM forms the basement membrane of the Müller cells. It
consists of type IV collagen which is associated with glyco-
proteins and contributes to vitreoretinal adhesion and type
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XVIII which binds opticin. Opticin is a class III small
leucine-rich repeat protein which binds to heparin sulfate
contributing to vitreoretinal adhesion [3]. The strength of
vitreous attachment to the surrounding tissue, including lens,
differs according to location. The vitreous is known to be
most firmly attached at the vitreous base, the optic nerve
and macula, and over retinal vessels.
The vitreous body is routed by the Cloquet’s canal, a
remnant of the hyaloid artery, which arises from the
Martegiani’s space at the optic disc to the retrolental
space known as the Berger’s space. Unlike the vitreous
base and cortex, the vitreous core does not contain hyalo-
cytes and is usually the area sampled in proteomic studies
because it is the simplest to acquire. All vitreous struc-
tures undergo characteristic changes with ageing, includ-
ing progressive liquefaction and, in some cases, posterior
vitreous detachment.
3.2. Chemistry. The vitreous is composed of over 98% water.
Between 15% and 20% of water is bound to proteins and
glycosaminoglycans. Primate studies have demonstrated that
the remaining portion is free [4].
3.2.1. Proteins. The average vitreous concentration of pro-
teins is 1200μg/mL. Albumins (40%) and immunoglobulins
are the most prevalent. Iron-binding proteins such as trans-
ferrin are synthesized in the vitreous itself and have a protec-
tive role in the event of small vitreous haemorrhages via the
prevention of iron toxicity [5].
Collagens are insoluble proteins of the vitreous. They
form a three-dimensional meshwork within the vitreous
gel. Collagen types II, IV, V/XI, VI, and IX are present, with
collagen type II to be the most prevalent (65%), followed by
type IX (25%), type V/XI (10%), and type IV (<10%) [6]. In
vitro studies have demonstrated that Müller cells are able to
synthesize collagens, and therefore these cells are thought
to generate the vitreous collagens [7].
3.2.2. Glycosaminoglycans. Glycosaminoglycans (GAGs) are
important constituents of the vitreous. They are extracellular
matrix polysaccharides that contain repeating disaccharide
units. Three major groups of GAGs are present: hyaluronic
acid (HA), chondroitin sulfate, and heparan sulfate.
(1) Hyaluronic acid. Hyaluronic acid (also called hyaluronan)
is unique among the GAGs in that it does not contain sul-
fate and it is not found covalently attached to proteins
forming a proteoglycan. Hyaluronic acid polymers are very
large (molecular weights of 100,000–10,000,000DA) and
can displace a large volume of water. The immense size
of these molecules makes them excellent lubricators and
shock absorbers within the joints and the vitreous. The
ageing process creates two structural changes: depolymeri-
zation of HA and the subsequent loss of collagen IX. The
absence of collagen IX induces aggregation of collagen II
fibrils (syneresis) and formation of fluid-filled lacunae
(synchisis) [8].
(2) Chondroitin sulfate. Chondroitin sulfate is a sulfated
GAG composed of a chain of alternating sugars (N-acetyl-
galactosamine and glucuronic acid). It is usually attached
to proteins as part of a proteoglycan. In the vitreous, it
appears in the form of two proteoglycans: versican and
type IX collagen [9]. It is important in maintaining the
structural integrity of the tissue and provides resistance
against compression.
(3) Heparan sulfate. Heparan sulfate has been identified in
small amounts in the vitreous, and its role is to maintain
adequate spacing between the collagen fibrils. It may also
facilitate the regulation of a wide variety of biological pro-
cesses including development, angiogenesis, and blood
coagulation [10], as well as maintaining vitreoretinal adhe-
sion in collaboration with opticin.
3.2.3. Ascorbic acid and cells. Ascorbic acid is found in
higher concentrations in the vitreous body than in the
plasma [11]. It has an important role in the process of
ageing liquefaction and can inhibit neovascularization, as
well as increase the proliferation of hyalocytes. Recent
studies have shown that the antioxidant properties of
ascorbic acid can also reduce early cataract formation
[12]. Vitreous body contains three types of cellular ele-
ment: hyalocytes, fibroblasts/fibrocytes, and macrophages.
Fibroblasts and hyalocytes are present on the vitreous
surface, and they are also involved in the phagocytosis
and/or secretion of collagen.
3.3. Physical Properties. The vitreous is not completely homo-
geneous, an effect resulting from the presence of so many
components. The viscoelastic properties of the vitreous result
from the interaction between long collagen fibrils and HA. It
is well known that numerous ions in the interior travel from
the dense and viscous portions (the vitreous base) to the
anterior part. This can affect the release and dissemination
of intravitreous drugs.
Although the vitreous has not aroused scientific interest
for many years, it has numerous and important roles, with
the key functions being to (1) sustain the growth, volume,
and elasticity of the eye (structural function); (2) maintain
transparency and improve the accommodation (optical
function); (3) create a barrier to biochemical substances
(barrier function); and (4) provide substances for nutrition
and metabolism (nutritional function).
3.3.1. Structural function. Recent studies have shown that the
growth of the vitreous may modify the growth of the retinal
pigment epithelium (RPE) through the production of HA
[13]. The vitreous protects the retina and the other struc-
tures from the low-frequency mechanical stress, friction,
and vibration that are both common and constant in every-
day life. Its viscoelasticity acts as an important shock
absorber against physical impact, providing more than a
space-filling function, particularly in younger people.
3.3.2. Optical function. The most important role of the vitre-
ous is to maintain transparency, enabling the passage of light
rays toward the retina. It transmits visible and near-infrared
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light, in a similar manner to the aqueous [14]. Little light
scattering occurs in the vitreous due to the large HA mole-
cules that separate collagen fibers. By supporting the lens
capsule, it also aids the accommodation process.
3.3.3. Barrier function. The vitreous can protect the eye,
acting as a barrier to various biochemical substances and
cells. In this manner, it helps prevent bacterial infection,
although it can act as a growth surface for some viral
agents. In the healthy eye, the vitreous is an important
part of the blood-ocular barrier, inhibiting neovasculariza-
tion and inflammation.
3.3.4. Nutritional function. Other important functions of
the vitreous body are metabolism and the regulation of
intraocular oxygen through ascorbate concentration [12].
Consuming oxygen via an ascorbate-dependent mecha-
nism protects the lens from oxidative damage and reduces
cataract formation.
4. The Ideal Vitreous Substitute
The ideal vitreous substitute is similar to the native vitreous
in both structure and function. It should have similar visco-
elastic properties and maintain a normal intraocular pressure
(IOP) in order to support the ocular structures in their cor-
rect position. It should be optically transparent while allow-
ing the circulation of ions and electrolytes. As a substitute,
it should be easy to manipulate and self-renewable in order
to require a single implantation. It should also be nontoxic
to other ocular structures, biocompatible, nonbiodegradable,
readily available at reasonable cost, and easy to store [15]. All
vitreous substitutes currently have positive and negative
characteristics. New research is underway to discover the
ideal vitreous substitute.
5. Vitreous Substitutes
There are three major categories of substitute: gases (air,
expansile gases), liquids (salt solution, perfluorocarbon
liquids, semifluorinated alkanes, silicone oil, etc.), and
polymers (hydrogels, smart hydrogels, and thermosetting
hydrogels) [15].
5.1. Gases
5.1.1. Air. Air present in the vitreous cavity is colourless and
inert. It was first used by Ohm in 1911 to repair retinal
detachment [15]. Air is inexpensive and easy to find. It
remains in the eye for a few days before being replaced by
the aqueous humour, thereby reducing its tamponade effect.
It is easily absorbed by red blood cells and therefore diffuses
quickly into the blood circulation. This is a negative feature
of air as a vitreous substitute. Another negative character-
istic is its low refractive index (approximately 1.000293
nanometers), which causes complete light reflection and
therefore poor optical function [16]. Its use is limited to
pneumatic retinopexy at the end of vitrectomy surgery
and as an emergency option.
5.1.2. Other Gases. Intraocular gas tamponades have been an
important part of vitreoretinal surgery since 1970. Today,
sulfur hexafluoride (SF6) and perfluoropropane (C3F8) are
increasingly being used in the treatment of many compli-
cated vitreoretinal diseases. Both these gases are heavier than
air, colourless, odourless, and nontoxic. They maintain their
tamponade effect due to their high surface tension and the
diffusion of other gases from the circulation. In 1993, the
U.S. Food and Drug Administration approved their use for
pneumatic retinopexy [15]. Sulfur hexafluoride expands to
double the injected volume within 1 to 2 days and lasts in
the vitreous cavity for 1 to 2 weeks. Perfluoropropane
expands to about four times its original volume in 72 to 96
hours and lasts for 6 to 8 weeks. For this reason, patients
are usually advised to delay air travel and avoid high altitudes
for about 2 weeks and 6 weeks following the administration
of sulfur hexafluoride and perfluoropropane, respectively.
Due to their buoyancy, intraocular gas tamponades
maintain the position of the retina against the RPE, but
this effect is limited on the upper part of the bubble and
does not affect the inferior retina. For this reason,
awkward face-down positioning is required for several
days following administration. Adverse effects include an
increase of IOP during surgery and, for a few days after
injection, gas-induced cataract formation and corneal
endothelial changes [17, 18, 19].
5.2. Liquids
5.2.1. Perfluorocarbon Liquid (PFCL). Perfluorocarbon
liquid is a fluorochemical in which all the hydrogen atoms
are replaced by fluorine [20]. PFCL has a high specific
gravity of between 1.76 and 2.03 g/mL with low surface
tension and viscosity and an optical transparency. PFCL
was initially used in medicine when it was discovered to
carry oxygen atoms in the same manner as the blood [21]. In
1987, Chang et al. used PFCL for the first time in retinal
detachment with severe proliferative vitreoretinopathy
[22, 23]. During vitrectomy, PFCL flattens the detached
retina and displaces the subretinal fluid. Furthermore, its
transparency facilitates its ease of use during procedures
and intraoperative photocoagulation.
The applications of PFCL are, in part, limited to intra-
operative use due to its long-term toxicity. This toxicity
begins in the inferior retina with mechanical damage to cells
via compression and disorganization of the retinal structure
and emulsification six days after surgery [24]. In addition,
young patients are at a high risk for developing severe
ocular inflammation. Recent developments in PFCL have
focused on perfluorocarbon-perfused vitrectomy, in which
oxygenated or nonoxygenated PCFL is used instead of bal-
anced salt solutions [20, 25, 26].
5.2.2. Semifluorinated Alkanes (SFAs). Semifluorinated
alkanes were identified in 2000 as a new class of compounds
with outstanding properties for use in ophthalmology [15].
They have a perfluorocarbon and hydrocarbon segments,
and they are soluble in PFCL, hydrocarbons, and silicone oils
with a preferred refraction index (1.3). They are physically
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inert, colourless, and heavier than water (specific gravity of
1.35 g/mL). The lower specific gravity results in less retinal
damage than PCFL, and as such SFAs can be used as a tem-
porary endotamponade for periods from 2 to 3 months
[27]. Their collateral effects may include cataract, emulsifica-
tion, and soft epiretinal membrane [27]. Recently, they have
been used in a mixture of silicon oil and SFA.
5.2.3. Silicone Oil (SO). Silicone oil is a liquid polymerized
siloxane with organic side chains. It is a hydrophobic polymer
with a specific gravity slightly less than water (0.97 g/mL) and
a refractive index similar to that of the vitreous [15]. All SO
polymers are of commercial interest for their stability, lubri-
cating properties, and as a vitreous substitute, with high
surface tension and viscosity, ease of removal, low toxicity,
and transparency. For these reasons, they are the only
substance currently accepted for long-term vitreous replace-
ment [15, 28]. Due to their buoyancy, SOs have a tamponade
force higher at the apex, facilitating the preservation of ana-
tomical integrity. They are used for complicated retinal
detachment, when postoperative airplane travel is planned,
and in uncooperative patients.
SO is available in several viscosities, but 1000 and 5000
centistokes are used clinically. SO is usually removed after 3
to 6 months once the retina has attached and retinal traction
is absent [15].
Although SO is a good vitreous substitute, it has several
disadvantages:
(1) Tamponade of the inferior retina is difficult due to its
low specific gravity.
(2) Emulsification in small droplets into the aqueous can
cause proliferative vitreoretinopathy, failed retinal
detachment, inflammation, secondary glaucoma,
and keratopathy [29, 30]. With the advent of micro-
incision vitreoretinal surgery (MIVS), less viscous
silicone oils are preferred. They can be easily intro-
duced and removed via small instruments, but they
are easier to emulsify. For this reason, new silicone
oils with an increased extensional viscosity are under
investigation [29].
(3) Increased IOP is common after SO implantation.
This could be caused by pupillary block glaucoma,
overfill of silicone oil, and chronic elevation due
to emulsification in the trabecular meshwork and
trabeculitis [29].
(4) Decreased choroidal thickness three months fol-
lowing SO implantation [31]. This may be caused
by the failure of Müller cells to circulate potassium
and the subsequent potassium accumulation, reti-
nal degeneration, and inner retinal and choroidal
thinning [32].
(5) Intracranial migration through the optic nerve to the
lamina cribrosa and the optic chiasm with the devel-
opment of central scotoma. This complication is very
rare and usually occurs in patients with optic nerve
abnormalities and glaucoma [33].
5.2.4. Heavy Silicone Oil (HSO).Heavy silicone oil is a tampo-
nade agent formed from a mixture of SO and partially fluori-
nated octane (PFA) that is heavier than water. For this
reason, it has been used for complex retinal detachment
involving the inferior part of the retina complicated by prolif-
erative vitreoretinopathy. In 2011, the heavy silicone oil
study [34] compared standard SO with HSO in the treatment
of inferior retinal detachment. Although superiority of a
heavy tamponade was not shown, the study demonstrated a
good intraocular tolerance of HSO and no significant emulsi-
fication [15].
Complications of HSO include cataract, anterior
segment inflammation, emulsification, and elevated IOP
[15, 19, 35, 36].
5.2.5. Hydrogels. Cross-linked hydrogels are synthetic poly-
mer networks that are expanded throughout their volume
by water. For this reason, they can melt in water without
dissolving. Hydrogels have favourable properties such as
transparency, biocompatibility, and mechanical flexibility
which have led to their widespread application in ophthal-
mology as soft contact lenses, intraocular lenses, drug
delivery systems, and adhesion for wound repair [37].
Hydrogels can be divided into hydrogels and “smart
hydrogels.” Smart hydrogels can create a three-dimensional
structure in response to a variety of signals including pH
variation, temperature, light, pressure, chemicals, and electric
fields [38].
To date, these polymers have only been used on an exper-
imental basis. A major disadvantage is their activation of the
immune system, resulting in intravitreal inflammation and
phagocytosis by macrophages in the vitreous, neuroretina,
and subretinal spaces [39]. In addition, they are difficult to
sterilize because heat sterilization may cause a degradation
of their physical structure. More research is needed to opti-
mize the use of these new molecules as vitreous substitutes.
6. Future Vitreous Substitutes
In the recent years, bioengineering studies using rabbit
models have shown promising results in a capsular artificial
vitreous body made from elastomer rubber with a valve
system full of SO or a balanced solution [40]. However, the
biocompatibility of a synthetic implant with the human eye
is yet untested.
The properties of new hydrogels make them promising
candidates as infill biomaterials for the treatment of retinal
detachment. Hayashi et al. reported a new class of hydrogel
with extremely low swelling pressure which functioned as
an artificial vitreous body for over a year without adverse
effects in the eyes of rabbits [41].
Another fascinating possibility for the future is the use
of cell culture and gene therapy to artificially synthesize
the vitreous via the proliferation of hyalocytes [42]. This
research has been aided by the use of reverse transcriptase
polymerase chain reaction to analyze and compare the
expression profiles of several genes involved in synthesis
of the vitreous [43].
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7. Microincision Vitreoretinal Surgery and
Vitreous Substitutes
Considerable progress has been recently made in the field of
vitreoretinal surgery. One of the most important advance-
ments is the development of small-gauge suturless transcon-
junctival surgery, also known as minimally invasive vitreous
surgery (MIVS). This system uses microcannulas and
trocars of 23G (0.64mm), 25G (0.51mm) and 27G
(0.40mm), and other instrumentation smaller than tradi-
tional 20G (0.9mm) vitrectomy. This new procedure has
introduced many benefits, including a reduction of postop-
erative inflammation at the sclerotomy site, the need for less
tissue manipulation, easier recovery, and a decrease in
surgical complications.
Tamponades have begun to adapt with this new type of
vitreoretinal surgery. The key feature of vitreous substitutes
used in MIVS is a low viscosity, in particular for liquids
and notably for SO. A less viscous oil would be user-friendly,
but an oil with greater viscosity would be less likely to
emulsify [44]. New SO has an increasing extensional viscosity
with a greater resistance to emulsification and an improved
ease of handling.
In accordance with Poiseuille’s law, which evaluates the
radius and the length of a tube to calculate the flow of a fluid,
MIVS uses special devices including a large syringe, a short
infusion line, and a nondistensible material to reduce
resistance during the injection and removal of SO [44].
The surgical technique used to inject SO into the eye has
also changed with MIVS. There is a diffuse consensus to per-
form air-silicone exchange instead of fluid-silicone exchange
(unused due to the high risk of undesired subretinal silicone
drops) or PFCL-silicone exchange (direct exchange). This is
preferred to the direct exchange usual for uncomplicated ret-
inal detachment with mild periphery or posterior pole break
because it is easier to inject SO using a cannula instead of an
infusion line.
The removal of SO with MIVS requires more time than
the same procedure using a 20G system, but requires less
time positioning and removing trocars.
Surgeons have a choice of many tamponades for use with
MIVS, each with advantages over the surgical complications
associated with 20G vitrectomy, enabling selection appropri-
ate to the underlying disease [45].
8. Conclusion
For many years, it was thought that the vitreous had a
marginal role in the anatomy and function of the eye. Only
with the advent of new surgical techniques was its impor-
tance in maintaining an optimal environment for the retina
and the other surrounding tissues recognized.
For this reason, research was originally focused on
finding a vitreous substitute with the same physical and
biochemical properties of the original vitreous.
In recent years, with the advent of MIVS, it has been
necessary to modify the physical structure of the most
commonly used vitreous substitutes.
A new generation of vitreous substitutes is under devel-
opment to satisfy the need for a physiologically equivalent
and long-lasting substitute [40, 41, 42, 43].
Future developments based on stem cells and gene
therapy may go some way to fulfill the needs of both patients
and ophthalmic surgeons.
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